Original Research

DOI: 10.4244/EIJ-D-23-01033

Outcomes of tricuspid transcatheter edge-to-edge repair in subjects with endocardial leads

Björn Goebel1, MD; Philipp Lurz2, MD, PhD; Thomas Schmitz3, MD; Raffi Bekeredjian4, MD; Georg Nickenig5, MD; Helge Mollmann6, MD; Ralph Stephan von Bardeleben7, MD; Alexander Schmeisser8, MD; Megan Heitkemper9, PhD; Iskandar Atmowihardjo10, MD; Rodrigo Estévez-Loureiro11, MD; Erwan Donal12, MD

Abstract

Background: Transcatheter edge-to-edge repair (TEER) using the TriClip tricuspid valve repair system has emerged as a therapy for tricuspid regurgitation (TR). Patients with TR undergoing TEER commonly present with an endocardial lead across the tricuspid valve (TV).

Aims: We sought to examine the effectiveness and safety of tricuspid TEER (T-TEER) in subjects with endocardial leads in the bRIGHT EU Post-Approval Study (PAS).

Methods: The bRIGHT EU PAS is a prospective, single-arm, open-label, multicentre, post-market registry conducted at 26 sites in Europe. Echocardiographic assessments of endocardial lead placement, interaction, and TR grade were performed at a core laboratory.

Results: Of the 511 enrolled subjects, a total of 110 had an endocardial lead, and in 80.7% of these subjects, TR was at least partially related to the lead. At 30 days, 71% of subjects with endocardial leads had TR of moderate or less. The percentage of subjects with endocardial leads categorised as New York Heart Association Functional Class I-II increased from 17% at baseline to 75% at 30 days (p<0.0001), and quality of life with the Kansas City Cardiomyopathy Questionnaire showed a mean improvement of 20±24 points from baseline to 30 days (p<0.0001). T-TEER was safe in subjects with endocardial leads, with similar rates of events, including TV reintervention/reoperation and TV surgery, to those in subjects without leads. No reports of lead malfunction were reported.

Conclusions: In the bRIGHT EU PAS, T-TEER using the TriClip system was safe and effective in severe TR subjects with an endocardial lead across the TV.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 5
Mar 3, 2025
Volume 21 Number 5
View full issue


Key metrics

Suggested by Cory

CLINICAL RESEARCH

10.4244/EIJ-D-16-00949 Feb 3, 2017
Transcatheter treatment of severe tricuspid regurgitation using the edge-to-edge repair technique
Braun D et al
free

Original Research

10.4244/EIJ-D-24-01174 Aug 4, 2025
Transcatheter valve repair of tricuspid regurgitation: 1-year outcomes from the TriCLASP study
Baldus S et al

10.4244/EIJV15I10A159 Nov 15, 2019
The five Ws of transcatheter tricuspid valve repair: Who, What, When, Where, and Why
Williams A et al
free

EXPERT REVIEW

10.4244/EIJ-D-17_00487 Sep 24, 2017
Transcatheter tricuspid valve intervention: state of the art
Taramasso M and Maisano F
free

Editorial

10.4244/EIJ-E-25-00006 Mar 3, 2025
Tricuspid annuloplasty: a piece of the puzzle or the whole picture?
Nickenig G and Vogelhuber J
free

Editorial

10.4244/EIJ-E-25-00035 Aug 4, 2025
The promise and pitfalls of registries for transcatheter tricuspid valve intervention
Hahn R
free

SPECIAL REPORT

10.4244/EIJV11I13A296 Apr 20, 2016
First transfemoral percutaneous edge-to-edge repair of the tricuspid valve using the MitraClip system
Wengenmayer T et al
free
Trending articles
95.7

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
61.2

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free
56.1

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
56.1

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
35.45

State-of-the-Art

10.4244/EIJ-D-23-00448 Jan 15, 2024
Coronary spasm and vasomotor dysfunction as a cause of MINOCA
Yaker ZS et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved